Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.
Alex A. Adjei, MD, PhD
Advertisement
Articles by Alex A. Adjei, MD, PhD
Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education
Advertisement
Latest Updated Articles
Dr. Adjei on the Need for Targeted Therapy EducationJune 12th 2012
Dr. Adjei on Adverse Events From MEK InhibitorsSeptember 11th 2013
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
5